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Foreword
“Do occupational exposures to engineered nanoparticles pose an unintended risk 
of adverse health effects?” This is not an abstract or theoretical question that prac­
titioners have the luxury of debating for years before it becomes a reality. Nanotech­
nology is a reality, with potential for great growth in the 21st Century. Workers are 
already engaged in processes in which they may be exposed to materials that never 
existed before in nature. We do not fully know how these engineered nanoparticles 
may enter the body, where they may travel once inside, or what effects they may have 
on the body’s systems. We do not fully know whether or how effects may differ for 
chemically or structurally different particles at the nanoscale. Diverse stakeholders 
have agreed that research to address these questions is essential for the responsible 
development of nanotechnology.
As research progresses to answer those questions, the National Institute for Oc­
cupational Safety and Health (NIOSH) has recommended prudent precautionary 
interim measures for reducing work-related exposures and assessing potential risk. 
In the hierarchy of prevention, it is important to consider where it may be of value 
to provide medical screening of workers who may be exposed to a potential health 
hazard, but who may be asymptomatic—that is, who have no identifiable symptom 
of an occupational disease. On the frontiers of nanotechnology, where as yet little 
data exist for assessing risk with confidence, it is difficult to recommend specific 
screening tests. NIOSH has sought a wide range of opinions on the matter and along with its own review of the scientific literature presents this interim guidance for 
medical screening and hazard surveillance. The evidence base on the health effects 
of engineered nanoparticles is rapidly growing and NIOSH will continue to monitor 
and assess it and will update those recommendations as more definitive information 
becomes available.
Christine M. Branche, Ph.D.Acting Director
National Institute for Occupational 
Safety and Health Centers for Disease Control 
and Prevention
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Executive Summary
Concerns have been raised about whether workers exposed to engineered nanopar­
ticles are at increased risk of adverse health effects. The current body of evidence 
about the possible health risks of occupational exposure to engineered nanopar­
ticles is quite small. While there is increasing evidence to indicate that exposure 
to some engineered nanoparticles can cause adverse health effects in laboratory 
animals, no health studies of workers exposed to the few engineered nanoparticles 
tested in animals have been published. The purpose of this document from the Na­
tional Institute for Occupational Safety and Health (NIOSH) is to provide interim 
guidance about whether specific medical screening, including performing medical 
tests on asymptomatic workers, is appropriate for these workers.
Medical screening is only one part of what should be considered a complete safety 
and health management program. An ideal safety and health management program 
follows a hierarchy of controls and involves various occupational health surveil­
lance measures. Since specific medical screening of asymptomatic workers exposed 
to engineered nanoparticles has not been extensively discussed in the scientific lit­
erature, this document makes recommendations based upon what is known until more rigorous research can be performed.
Currently there is insufficient scientific and medical evidence to recommend the 
specific m edical screening of workers potentially exposed to engineered nanopar­
ticles. Nonetheless, this lack of evidence does not preclude specific medical screen­
ing by employers interested in taking precautions beyond existing industrial hygiene 
measures. If nanoparticles are composed of a chemical or bulk material for which medical screening recommendations exist, these same screening recommendations 
would be applicable for workers exposed to engineered nanoparticles as well.
As research into the hazards of engineered nanoparticles continues, vigilant reas­
sessment of available data is critical to determine whether specific medical screen­
ing is warranted for workers. In  the in terim , the fo llow ing recom m endations are 
provided fo r workplaces where workers m ay be exposed to  engineered nanopar­
ticles in  the course o f th e ir work:
• Take prudent measures to control exposures to engineered nanoparticles.
• C onduct hazard surveillance as the basis fo r im plem enting  controls.
• C ontinue use o f established m edical surveillance approaches.
NIOSH will continue to collect and evaluate new research findings and update its recom­mendations about medical screening programs for workers exposed to nanoparticles.
v
NIOSH will also continue to consider the strengths and weaknesses of establishing 
exposure registries for workers potentially exposed to engineered nanoparticles for 
future health surveillance and epidemiological studies.
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Interim Guidance for the Medical Screening and 
Hazard Surveillance for Workers Potentially 
Exposed to Engineered Nanoparticles
Introduction
Nanotechnology is a system of innovative 
methods for controlling and manipulating 
matter at the near-atomic scale to produce 
engineered materials, structures, and devices. 
Engineered nanoparticles are generally con­
sidered to include a class or subset of these 
manufactured materials with at least one di­
mension of approximately 1 to 100 nanome­
ters (www.nano.gov/html/facts/whatIsNano. 
html). At these scales, materials often exhibit 
unique properties beyond those expected at the 
chemical or bulk level that affect their physical, 
chemical, and biological behavior. The term 
“ultrafine” is also frequently used in the litera­
ture to describe particles with dimensions less 
than 100 nanometers that have not been inten­
tionally produced (e.g., manufactured) but are 
the incidental products of processes involv­
ing combustion, welding, or diesel engines. It 
is currently unclear whether a distinction in 
particle terminology is justified from a safety 
and health perspective if the particles have the 
same physicochemical characteristics.
The potential occupational health risks associ­
ated with the manufacture and use of nanoma­
terials are not yet clearly understood. Many en­
gineered nanomaterials and devices are formed 
from nanometer-scale particles (i.e., nanopar­
ticles) that are initially produced as aerosols or 
colloidal suspensions. Exposure to these mate­
rials during manufacturing and use may occur 
through inhalation, dermal contact, or inges­
tion; however, inhalation exposure is the main 
route of concern [ASCC 2006]. There is very 
limited information available about dominant 
exposure routes, the potential for exposure, 
and material toxicity.
At this time, society in general and companies 
in particular are faced with the dilemma of bal­
ancing a desire to expand a potentially boun­
tiful technology against the potential hazards 
that may result. The real risks from the technol­
ogy are not known, and the perceived risks are 
undetermined. In this regard, nanotechnology is no different from any other emerging tech­
nology. One of the first areas where exposures 
to engineered nanoparticles will occur is in the 
workplace. In the face of uncertainty about the 
hazards of nanoparticles, a corporate or soci­etal response (such as implementing appropri­
ate occupational health surveillance measures) 
may assure the public that appropriate efforts 
are being taken to identify and control poten­
tial hazards in a timely fashion.
Concerned individuals from government, in­
dustry, labor, and academia, together with oc­
cupational health professionals and medical 
personnel, have raised questions about whether 
workers exposed to engineered nanoparticles 
should be provided some type of medical sur­
veillance. The purpose of this document is to
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provide interim guidance concerning specific 
medical screening for these workers—that is, 
medical tests for asymptomatic workers—until 
additional research either supports or negates 
the need for this type of screening. The type and degree of screening recommended here is 
in addition to any medical surveillance taking 
place as part of existing occupational health 
surveillance efforts.
Background: A Brief Review of 
the Literature
Effects of Exposure to Ultrafine 
Particles
Results from epidemiological studies in the 
general population have shown associations be­
tween fine particulate air pollution and increased 
morbidity and mortality from respiratory and 
cardiopulmonary disease [Dockery et al. 1993; 
Ibald-Mulli et al. 2002; Pope et al. 2004]. Other 
studies have investigated specific markers of ef­
fect associated with exposure to the ultrafine 
particulate fraction of air pollution [Ruckerl et 
al. 2006]. Studies of workers exposed to ultrafine 
particles (e.g., diesel exhaust and welding fume) 
have reported elevated lung cancer risks [Steen­
land et al. 1998; Garshick et al. 2004; Antonini 
2003] while results from some animal studies 
have shown that many types of poorly soluble 
ultrafine particles can elicit a greater pulmonary 
inflammatory response than larger particles of 
the same composition on a mass for mass basis 
[Oberdörster et al. 1994; Lison et al 1997; Zhang 
et al. 2000, 2003; Brown et al. 2001; Höhr et al. 
2002; Duffin et al. 2007]. Toxicological studies 
indicate that the chemical and physical proper­
ties that influence the toxicity of ultrafine parti­
cles may also be relevant to mechanisms that in­
fluence the toxicological response to engineered 
nanoparticles [Castranova et al. 2000; Aitken et
al. 2004; Donaldson et al. 2005, 2006; Maynard 
and Kuempel 2005; Oberdorster et al. 2005a, 
b; Kreyling et al. 2006; Gwinn and Vallyathan 
2006; Borm et al. 2006; Helland et al. 2007]. 
Studies have also shown that physicochemical 
properties such as surface reactivity, chemical 
composition, crystal structure, and shape also 
influence the toxicity of nanoscale particles 
[Zhang et al. 1998; Dick et al. 2003; Warheit 
et al. 2007a, b]. Adverse effects reported from 
exposure to ultrafine particles have raised con­
cerns about workers exposed to engineered 
nanoparticles [Royal Society and Academy 
of Engineering 2004; Maynard and Kuempel 
2005; IRRST 2006; Nel et al. 2006; Schulte and 
Salmanca-Buentello 2007; Maynard 2007; Lam 
et al. 2006; Kuempel et al. 2007; Aitken et al. 
2004; ASCC 2006]
Effects of Exposure to Engineered 
Nanoparticles
Animal studies with some types of engineered 
nanoparticles have caused adverse lung effects 
(e.g., pulmonary inflammation and progressive 
fibrosis) [Lam et al. 2004, 2006; Shvedova et 
al. 2005; Takagi et al. 2008; Poland et al. 2008] 
and cardiovascular effects (e.g., inflammation, 
blood platelet activation, plaque formation, 
and thrombosis) [Radomski et al. 2005; Don­
aldson et al. 2006; Li et al. 2007]. Other studies 
have demonstrated that discrete nanoparticles 
may enter the bloodstream from the lungs and 
translocate to other organs [Oberdorster et 
al. 2002] while other studies have shown that 
discrete nanoparticles (35-37 nm count me­
dian diameter) that deposit in the nasal region 
may be able to enter the brain by translocation 
along the olfactory nerve [Oberdorster et al. 
2005(b); Elder et al. 2006]. A broader review 
of the human and animal data can be found 
in the NIOSH document Approaches to Safe
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Occupational Health 
Surveillance
NIOSH has historically recommended imple­
menting occupational health surveillance pro­
grams when workers are exposed to potentially 
hazardous materials. Occupational health sur­
veillance involves the ongoing systematic col­
lection, analysis, and dissemination of expo­
sure and health data on groups of workers for 
the purpose of preventing illness and injury. 
This information is frequently used for estab­
lishing and evaluating the hierarchy of pre­
ventive actions [Halperin 1996]. The general 
term occupational health surveillance includes 
medical and hazard surveillance. Occupational 
health surveillance is an essential component 
of an effective occupational safety and health program [Harber et al. 2003; NIOSH 2006b; 
Wagner and Fine 2008; Baker and Matte 2005]. 
While this document supports that concept, the main focus is whether a typical medical surveil­lance program that includes additional medical screening is warranted fo r workers potentially exposed to engineered nanoparticles.
Medical Surveillance
Medical surveillance targets actual health 
events or a change in a biologic function of an 
exposed person or persons. Medical surveil­
lance is a second line of defense behind the 
implementation of engineering, administra­
tive, and work practice controls including the 
use of personal protective equipment. NIOSH 
recommends the medical surveillance of work­
ers when they are exposed to hazardous ma­
terials. The elements of a medical surveillance 
program generally include the following:
Nanotechnology: A n Information Exchange with
N IO SH  [NIOSH 2006a]. 1. An initial medical examination and collec­tion of medical and occupational histories.
2. Periodic medical examinations at regularly 
scheduled intervals, including specific med­
ical screening tests when warranted.
3. More frequent and detailed medical exami­
nations as indicated on the basis of findings 
from these examinations.
4. Post-incident examinations and medical 
screening following uncontrolled or non­
routine increases in exposures such as spills.
5. Worker training to recognize symptoms of 
exposure to a given hazard.
6. A written report of medical findings.
7. Employer actions in response to identifica­
tion of potential hazards.
When the purpose of a medical surveillance 
program is to detect early signs of work-relat­
ed illness and disease, it is considered a type 
of medical screening, also referred to as medi­
cal monitoring and includes medical testing to 
detect preclinical changes in organ function or 
changes before a person would normally seek 
medical care and when intervention is benefi­
cial [Ashford et al. 1990; Baker and Matte 2005; 
Halperin et al. 1986; Harber et al. 2003; ILO 
1998]. The establishment of a medical screen­
ing program should follow established criteria 
[Halperin et al. 1986; Borak et al. 2006; Baker 
and Matte 2005; Harber 2003] and that specific 
disease endpoints must be able to be deter­
mined by the test selected (see Appendix A).
Frequent Uses for Medical 
Surveillance
Medical examinations and tests are used in 
many workplaces to determine whether an 
employee is able to perform the essential
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functions of the job, with or without reason­
able accommodation, without posing a direct 
and imminent threat to the safety or health of the worker or others. Workplace medical ex­
aminations must be conducted in compliance with the Americans with Disabilities Act of 
1990 (ADA) (Public Law No. 101-336). For 
example, this law prohibits making a job offer 
contingent upon the applicant’s submission to 
a medical examination. Still, medical examina­
tions and examinations conducted before plac­
ing a worker in a given job could potentially 
provide useful baseline information in a vari­
ety of ways. For example, even if there appears 
to be no reason for immediate concern about 
exposure to engineered nanoparticles in a par­
ticular workplace setting, this type of baseline 
data may benefit employers and workers alike 
if questions come up later regarding potential 
worker health problems associated with the 
specific engineered nanoparticle.
Medical surveillance of workers is also re­
quired by law when there is exposure to a spe­
cific workplace hazard. Although OSHA does 
not have a standard that specifically addresses 
occupational exposure to engineered nano­
particles, OSHA has a number of standards 
that require medical surveillance of workers. 
Workplaces with engineered nanoparticles 
comprised of chemicals addressed by current 
OSHA standards (Appendix B) are subject to 
the requirements of those standards, including 
the requirements for medical surveillance. In 
addition, medical surveillance of workers han­
dling engineered nanoparticles may also be 
triggered when workers are exposed to other 
hazardous substances (e.g., those listed in Ap­
pendix B) present in nanoparticle operations.
In addition to substance-specific standards, 
OSHA has standards with broader applicabil­
ity. For example, employers must follow the
medical evaluation requirements of OSHA’s 
respiratory protection standard [29 CFR 
1910.134] when respirators are necessary to 
protect worker health. This standard includes 
elements of medical surveillance. Likewise, the 
OSHA standard for occupational exposure to 
hazardous chemicals in laboratories [29 CFR 
1910.1450] requires medical consultation fol­
lowing the accidental release of hazardous 
chemicals.
NIOSH also recommends medical surveillance 
(including screening) of workers when there is 
exposure to certain occupational hazards (Ap­
pendix C). None of the hazards noted in Ap­
pendix C are identified as engineered nanopar­
ticles, but medical surveillance would apply to 
workers exposed to nanoparticles comprised 
of chemicals for which NIOSH has a recom­
mendation. The medical surveillance of these 
workers may provide useful information if 
questions arise in the future about the health 
effects of their exposure to nanoparticles.
Hazard Surveillance and Risk 
Management
Hazard surveillance involves identifying poten­
tially hazardous practices or exposures in the 
workplace and assessing the extent to which 
they can be linked to workers, the effective­
ness of controls, and the reliability of exposure 
measures [Sundin and Frazier 1989; Froines et 
al. 1989]. H azard  surveillance for engineered  
nanoparticles is an essential com ponent o f  
any occupational health  surveillance effort 
and is used for defin ing the elements o f the 
risk m anagem ent program . One component 
of a risk management program involves taking ac­
tion to minimize exposure to potential hazards. In 
the case of engineered nanoparticles, even in 
the absence of adequate health information, an
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understanding of potential worker exposures 
can form the basis for ongoing risk manage­
ment. Other critical elements of a risk man­
agement program include recognizing poten­
tial exposures and determining appropriate 
actions to minimize them (e.g., implementing 
engineering controls, employing good work 
practices, and using personal protective equip­
ment) [NIOSH 2006a]. Hazard surveillance 
should include the identification of work tasks 
and processes that involve the production and 
use of engineered nanoparticles, and should be 
viewed as one of the most critical components 
of any risk management program.
Discussion and Conclusions
Assessing the potential toxicity of engineered 
nanoparticles is at an early stage. A body of sci­
entific evidence has accrued from toxicology 
studies on selected engineered nanoparticles 
and from epidemiology studies of individu­
als exposed to ultrafine nanoparticles sug­
gests that some nanoscale particles may pose 
a health concern [Kuempel et al. 2007; Gwinn 
and Vallyathan 2006; Donaldson et al. 2006]. 
This evidence suggests that safety and health 
professionals should consider precaution­
ary management approaches in workplaces 
where there is exposure to engineered nano­
particles [Schulte and Salamanca-Buentello 
2007; NIOSH 2006a; Royal Society and Royal 
Academy of Engineering 2004; Borm et al. 
2006; Holman et al. 2006; IRSST 2006] such as 
the implementation of occupational risk man­
agement programs. Such approaches are de­
scribed in the NIOSH document Approaches to 
Safe Nanotechnology: An Information Exchange with NIOSH  [NIOSH 2006a].
The current body of evidence about the pos­
sible health risks of occupational exposures to
engineered nanoparticles is not sufficient to 
support the determination of specific medical 
screening to identify preclinical changes asso­
ciated with exposure to engineered nanopar­
ticles. No substantial link has been established 
between occupational exposure to engineered 
nanoparticles and adverse health effects. In 
addition, the toxicological research to date is 
insufficient to recommend such monitoring, 
the appropriate triggers for it, or components 
of it. As the volume of research on the poten­
tial health effects from exposure to engineered 
nanoparticles increases, continual reassessment 
will be needed to determine whether medical screening is warranted for workers who are 
producing or using engineered nanoparticles. 
NIOSH will continue to examine new research 
findings and update its recommendations on medical screening programs for workers ex­
posed to nanoparticles. Appendix D provides a 
brief discussion concerning occupational health 
programs that include medical screening and might serve as a model for future reference for 
one or more engineered nanoparticles. Appen­dix E provides discussion highlighting details of 
instances where sufficient evidence to support recommendations for specific medical screen­
ing for workers exposed to engineered nanopar­
ticles is lacking.
At this time, only a few types of engineered 
nanoparticles have been studied, and a clear 
and consistent picture of the relevant end­
points for workers has not yet emerged. Vari­
ous physicochemical parameters of nanopar­
ticles (e.g., composition, size, shape, surface 
characteristics, charge, functional groups, 
crystal structure, and solubility) appear to af­
fect toxicity [Oberdorster et al. 2005a; Borm 
et al. 2006; Warheit et al. 2007b; IRSST 2006]. 
It is not known whether size is the overriding 
parameter, though most studies show that size appears to be the major factor in enhancing the
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toxicity of engineered nanoparticles compared 
with the toxicity of larger particles of the same 
composition. Results from a limited number of 
experimental animal studies with engineered 
nanoparticles indicate the potential for respira­tory and circulatory effects [Aitken et al. 2004; 
Borm et al. 2006; ASCC 2006; IRRST 2006]; 
however, it is not clear which effects are most 
critical, whether they are dose-dependent, and 
whether these effects are relevant to human 
exposure. Additional studies are needed to 
determine the biological significance of differ­
ent physicochemical parameters and whether 
these parameters can be used to predict the 
potential toxicity of other untested engineered 
nanoparticles.
When occupational health surveillance is being 
established, it is necessary to understand the 
relative, absolute, and population-attributable 
risks to workers who are handling engineered 
nanomaterials. This includes understanding 
the hazard as well as the extent of exposure 
and ultimately the risk. Limited information 
is available on these topics, but exposures may 
be generally low relative to the airborne expo­
sures of the same material in larger but respi- 
rable particle sizes. The level of risk resulting 
from lower exposures to nanomaterials is un­
known. Ultimately, epidemiological studies of 
exposed workers will be needed to help assess 
exposure-response relationships. Although 
such studies are difficult to conduct, they are more likely than medical screening to clarify 
the relationship between exposure and adverse 
effects at this time.
Finally, there is not yet enough research to 
make categorical determinations of the hazards 
based on combinations of physicochemical fac­
tors [ASCC 2006; Aitken et al. 2004]. Although 
preliminary studies indicate that while specific 
medical screening may be warranted in the fu­
ture, insufficient information is now available 
to make any recommendations beyond hazard 
surveillance. NIOSH will continue to assess the 
scientific evidence and periodically update the 
guidance on medical screening.
Recommendations
Continued in vivo and in vitro toxicological re­
search is needed to identify potential health end­
points related to occupational exposure to engi­
neered nanoparticles. Epidemiological studies 
of exposed workers will be needed to establish 
associations between exposures to engineered 
nanoparticles and adverse health effects and to 
assess other potential exposure-response rela­
tionships. Research is needed to assess various 
candidate biological markers that may ultimate­
ly be used in medical screening, including mo­
lecular markers [Schulte 2005]. This research is 
needed to assess sensitivity, specificity, and pre­
dictive value of biomarkers and clinical tests that 
might be developed and used to screen workers’ 
health. Determining sufficient positive predic­
tive value of a screening modality to detect ad­
verse health effects early enough in the course 
of the disease to enable secondary prevention, is 
an important factor when considering medical 
screening efforts.
The following recommendations are provided 
for workplaces where workers may be exposed 
to engineered nanoparticles during the course 
of their work.
Take prudent measures to 
control exposures to engineered 
nanoparticles.
A prudent approach to controlling exposures 
to engineered nanoparticles has been described 
in the NIOSH draft document Approaches to
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Conduct hazard surveillance as the 
basis for implementing controls.
To establish prudent measures for controlling 
exposure to engineered nanoparticles, it is 
important to identify which jobs or processes 
involve the production or use of engineered 
nanoparticles. Employers should identify and 
document the presence of engineered nano­
particles in their workplaces and the work tasks associated with them. This information will 
serve as the basis for applying various control 
measures [NIOSH 2006a]. Hazard surveillance 
programs should be designed to address some 
or all of the following questions:
— What exposure agents are found in the 
workplace?
— Are standardized, reliable, and 
practical methods available for 
measuring workers’ exposures to the 
agents?
— What exposure metrics (e.g., mass, 
particle count, particle surface 
area) are most relevant to the most 
important health concerns?
— To what extent can specific exposures 
(e.g., nanoparticles) be linked to 
people?
— What actions have been taken 
to control potentially hazardous 
exposures?
— How effective are the controls (e.g., 
engineering)?
— Which agents affect the most workers?
— What jobs or industries are most likely 
to cause exposures to workers?
Safe Nanotechnology: A n  Information Exchange
with N IO SH  [NIOSH 2006a]. — What health effects are most likely related to these exposures?
— How are specific occupational exposures changing over time?
Continue use of established medical 
surveillance approaches.
Currently, there are many established uses for 
medical surveillance by employers and occu­
pational health practitioners (see Section 3.3). 
These may pertain to workers exposed to en­
gineered nanoparticles, but they are not spe­
cifically focused on them. Employers should 
continue using these established approaches to 
collect data that may be informative in the fu­
ture about whether there is an increase in the 
frequency of adverse health effects related to 
exposure to engineered nanoparticles. NIOSH 
continues to recommend occupational health 
surveillance as an important part of an effec­tive risk management program. Lack of evi­
dence for recommending medical screening 
for workers potentially exposed to engineered 
nanoparticles should not stop employers who 
want to take additional precautions, including 
medical screening, beyond those already es­
tablished. However, it is important to note that 
nonspecific medical testing can have negative 
consequences such as adverse effects resulting 
from tests (e.g., radiation from chest radio­graphs), creating unnecessary anxiety in work­
ers and employers from false-positive screen­
ing tests, and the economic ramifications of 
additional diagnostic evaluations [Nasterlack 
et al. 2007; Schulte 2005; Marcus et al. 2006].
NIOSH will continue to evaluate the usefulness of establishing exposure registries in work­
places were there is potential exposure to engi­
neered nanoparticles. As the understanding of 
occupational exposure to engineered nanopar­
ticles increases, the development of exposure
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registries may be needed to form the basis for 
future epidemiologic research (Appendix F). 
Such registries probably need to cover work­
ers from numerous companies to reflect the 
diversity of exposures, to account for the small 
number of workers exposed at a given site, and 
to assess chronic health effects.
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APPENDIX A • Critical Aspects of an 
Occupational Medical Screening Program
Assessment of workplace hazards
Identification of target organ toxicities for each hazard
Selection of test for each “screenable health effect”
Development of action criteria
Standardization of data collection process
Performance of testing
Interpretation of test results
Test confirmation
Determination of work status
Notification
Diagnostic evaluation
Evaluation and control of exposure
Recordkeeping
[Baker and Matte 2005].
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APPENDIX B • OSHA Standards That Include 
Requirements for Medical Surveillance
2-acetylaminofluorene ethylene oxide
acrylonitrile ethyleneimine
4-aminodiphenyl formaldehyde
inorganic arsenic hazardous waste
asbestos lead
benzene methyl chloromethyl ether
benzidine alpha-naphthylamine
bis-chloromethyl ether beta-naphthylamine
1,3-butadiene methylene chloride
coke oven emissions 4-nitrobiphenyl
cotton dust n-nitrosodimethylamine
dibromochloropropane beta-propriolactone
3.3’-dichlorob enzidine vinyl chloride
4-dimethylamino azob enzene methylenedianiline
cadmium bloodborne pathogens
occupational exposure to hazardous chemicals in the laboratories chromium (VI)
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APPENDIX C • Hazards for Which NIOSH Has 
Recommended the Use of Medical Surveillance
NIOSH publication num ber Title and date NTIS stock num ber
76-195 Acetylene (1976) PB 267068
77-112 Acrylamide (1976) PB 273871
78-116 Acrylonitrile (1978) PB 81-225617
77-151 Alkanes (C5-C8) (1977) PB 273817
76-204 Allyl Chloride (1976) PB 267071
74-136 Ammonia (1974) PB 246699
78-216 Antimony (1978) PB 81-226060
74-110 Arsenic, Inorganic (1974), (Revised 1975) PB 228151
75-149 Arsenic, Inorganic (1975) PB 246701
72-10267 Asbestos (1972) PB 209510
77-169 Asbestos (Revised) (1976) PB 273965
78-106 Asphalt Fumes (1977) PB 277333
74-137 Benzene (1974) PB 246700* Benzene (Revised) (1976) PB 83-196196
77-166 Benzoyl Peroxide (1977) PB 273819
78-182 Benzyl Chloride (1978) PB 81-226698
72-10268 Beryllium (1972) PB 210806* Beryllium (Revised) (1977) 
2-Butoxyethanol[See: Ethylene Glycol Monobutyl Ether]
PB 83-182378
77-122 Boron Trifluoride (1976) PB 274747
76-192 Cadmium (1976) PB 274237
77-107 Carbaryl (1976) PB 273801
78-204 Carbon Black (1978) PB 81-225625
76-194 Carbon Dioxide (1976) PB 266597
(cont:
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NIOSH publication number Title and date NTIS stock number
77-156 Carbon Disulfide (1977) PB 274199
73-11000 Carbon Monoxide (1972) PB 212629
76-133 Carbon Tetrachloride (1975) PB 250424* Carbon Tetrachloride (Revised) (1979) PB 83-196436
76-170 Chlorine (1976) PB 266367
75-114 Chloroform (1974) PB 246695* Chloroform (Revised 1979) PB 83-195856
77-210 Chloroprene (1977) PB 274777
73-11021 Chromic Acid (1973) [Revised; see Chromium VI] PB 222221
760-129 Chromium VI (1975) PB 248595
78-191 Coal Gasification Plants (1978) PB 80-164874
95-106 Coal Mine Dust PB 96-191713
78-107 Coal Tar Products (1977) PB 276917
82-107 Cobalt (1981) PB 82-182031
73-11016 Coke Oven Emissions (1973) PB 216167
80-106 Confined Spaces, Working in Construction [See: Excavations] (1979) PB 80-183015
75-118 Cotton Dust (1974) PB 246696
78-133 Cresol (1978) PB 86-121092
77-108 Cyanide, Hydrogen and Cyanide Salts (1976) PB 266230
78-115 Dibromochloropropane (1978) 1,2-Dichloroethane [See: Ethylene Dichloride] PB 81-228728
96-104 2-Diethylaminoethanol (1996) PB 96-197371
78-215 Diisocyanates (1978) PB 81-226615
78-131 Dinitro-ortho-Cresol (1978) PB 80-175870
77-226 Dioxane (1977) PB 274810
76-128 Elevated Work Stations, Emergency Egress from (1975) PB 248594
76-206 Epichlorohydrin (1976) PB 81-227019
77-221 Ethylene Dibromide (1977) PB 276621
76-139 Ethylene Dichloride (1976) PB 85-178275
78-211 Ethylene Dichloride (1,2- Dichloroethane) (Revised) (1978) PB 80-176092
(continued)
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NIOSH publication number Title and date NTIS stock number
90-118
91-119 
83-103 
*
77-152
76-103
77-193
77-126
85-116 
79-133
78-166 
83-126 
89-106 
83-125
72-10269
86-113 
78-172
76-143
77-158
78-155
75-126
76-142 *
78-173
73-11010 
78-158
Ethylene Glycol Monobutyl Ether and Ethylene Glycol Monobutyl Ether Acetate (1991)
Ethylene Glycol Monomethyl Ether, Ethylene Glycol Monoethyl Ether, and Their Acetates
Excavations, Development of Draft Construction Safety Standards for, Volume 1 (1983)
Excavations, Development of Draft Construction Safety Standards for, Volume 2 (1983)
Fibrous Glass (1977)
Fluorides, Inorganic (1975)
Fluorocarbon Polymers, Decomposition Products of (1977)
Formaldehyde (1976)
Foundries (1985)
Furfuryl Alcohol (1979)
Glycidyl Ethers (1978)
Grain Elevators and Feed Mills (1983)
Hand-Arm Vibration (1989)
Guidelines for Controlling Hazardous Energy During Maintenance and Servicing (1983)
Hot Environments (1972)
Hot Environments (Revised 1986)
Hydrazines (1978)
Hydrogen Cyanide [See: Cyanide, Hydrogen and Cyanide Salts]
Hydrogen Fluoride (1976)
Hydrogen Sulfide (1977)
Hydroquinone (1978)
Identification System for Occupationally Hazardous Materials (1974)
Isopropyl Alcohol (1976)
Kepone (1976)
Ketones (1978)Labeling [See: Identification System for Occupationally Hazardous Materials]
Lead, Inorganic (1972)
Lead, Inorganic (Revised) (1978)
Lockout/Tagout [See: Hazardous Energy]
PB 91-173369
PB 92-167147
PB 84-100569
PB 83-233353
PB 274195 
PB 246692 
PB 274727
PB 273805 
PB 86-213477 
PB 80-176050 
PB 81-229700 
PB 83-138537 
PB 90-168048 
PB 84-199934
PB 210794 
PB 86-219508 
PB 81-225690
PB 81-226516 
PB 274196 
PB 81-226508 
PB 246698
PB 273873 
PB 83-196170 
PB 80-176076
PB 214265 
PB 81-225278
(continued)
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NIOSH publication number Title and date NTIS stock number
76-188
76-205
73-11024
76-148
77-106
76-138 
98-102
77-164 
76-141
78-212
76-149 
78-167
73-11001 
2006-123
98-126
83-127
77-115
84-115 
76-190
78-174 
76-196
76-137
77-225 
84-103 
88-101 
77-192 
2006-123
75-120
76-105 
83-119
74-111 *
74-128
Logging from Felling to First Haul (1976) 
Malathion (1976)
Mercury, Inorganic (1973)
Methyl Alcohol (1976)Methyl Chloroform [See: 1,1,1-Trichloroethane] 
Methyl Parathion (1976)
Methylene Chloride (1976)
Metalworking Fluids (1998)
Nickel, Inorganic (1977)
Nitric Acid (1976)
Nitriles (1978)
Nitrogen, Oxides of (1976)
Nitroglycerin and Ethylene Glycol Dinitrate (1978) 
Noise (1972)
Occupational Exposure to Refractory Ceramic Fibers
Occupational Noise Exposure 
Oil and Gas Well Drilling (1983)
Organotin Compounds (1976)
Paint and Allied Coating Products (1984) 
Parathion (1976)
Perchloroethylene [See: Tetrachloroethylene] 
Pesticides, Manufacture and Formulation 
Phenol (1976)
Phosgene (1976)
Polychlorinated Biphenyls (1977)
Precast Concrete Products Industry (1984)
Radon Progeny in Underground Mines (1988) 
Refined Petroleum Solvents (1977)
Refractory Ceramic Fibers (2006)
Silica, Crystalline (1974)
Sodium Hydroxide (1975)
Styrene (1983)
Sulfur Dioxide (1974)
Sulfur Dioxide (Revised) (1977)
Sulfuric Acid (1974)
PB 266411 
PB 267070 
PB 222223 
PB 273806
PB 274191 
PB 81-227027 
PB 99-133910 
PB 274201 
PB 81-227217 
PB 81-225534 
PB 81-226995 
PB 81-225526 
PB 213463
PB 98-173-735 
PB 84-242528 
PB 274766 
PB 85-178978 
PB 274192
PB 81-227001 
PB 266495 
PB 267514 
PB 276849 
PB 85-220051 
PB 88-173455 
PB 85-178267 
PB 2006-1123003 
PB 246697 
PB 246694 
PB 84-148295 
PB 228152 
PB 83-182485 
PB 233098
(continued)
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NIOSH publication number Title and date NTIS stock number
77-121 1,1,2,2-Tetrachloroethane (1976) PB 273802
76-185 Tetrachloroethylene (Perchloroethylene) (1976) PB 266583
78-213 Thiols: N-Alkane Mono, Cyclohexane, and Benzene (1978) PB 81-225609
78-179 o-Tolidine (1978) PB 81-227084
73-11023 Toluene (1973) PB 222219
73-11022 Toluene Diisocyanate (1973) [Revised; See: Diisocyanates] PB 222220
76-184 1,1,1-Trichloroethane (Methyl Chloroform) (1976) PB 267069
73-11025 Trichloroethylene (1973) PB 222222
77-127 Tungsten and Cemented Tungsten Carbide (1977) PB 275594
73-11009 Ultraviolet Radiation (1972) PB 214268
77-222 Vanadium (1977) PB 81-225658
78-205 Vinyl Acetate (1978) PB 80-176993* Vinyl Chloride (1974) PB 246691* Vinyl Halides (1979) PB 84-125699
77-140 Waste Anesthetic Gases and Vapors (1977) PB 274238
88-110 Welding, Brazing, and Thermal Cutting (1988) PB 88-231774
75-168 Xylene (1975) PB 246702
76-104 Zinc Oxide (1975) PB 246693
*Denotes the absence of a publication number or that recommendations were provided in testimony by NIOSH to the U.S. Department of Labor.NTIS [National Technical Information Service] Web site: http://www.ntis.gov
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APPENDIX D • Discussion of Occupational 
Health Surveillance Programs with Medical 
Screening
Occupational health surveillance programs ex­
ist that may be useful as models on which to 
base future efforts in the management of occu­
pational exposures to one or more engineered 
nanoparticles together with any potential health 
risk(s) related to those exposures.
Occupational exposures to metalworking fluids 
(MWF) have been implicated in health prob­
lems including a variety of dermatologic and respiratory health conditions. In the NIOSH  Criteria fo r a Recommended Standard: Oc­cupational Exposure to Metal Working Fluids 
[NIOSH 1998], medical monitoring (screening) 
is recommended by NIOSH as part of a com­plete MWF safety and health program. Similarly, 
in the Safety and Health Best Practices Manual for Metalworking Fluids [OSHA, 2008], OSHA 
recommends a model for a medical monitoring 
(screening) program and provides information 
on implementation. These recommended pro­
grams provide examples of how appropriate
occupational health surveillance principles 
may be applied toward prevention and con­
trol of occupational exposures and associated 
health risks. Although there are still scientific 
uncertainties related to occupational exposures 
to MWF that require further research, the rec­
ommendations for these medical monitoring 
programs are based on evaluation of extensive 
data concerning exposures, health effects, and 
exposure-health effect relationships. As noted 
in the NIOSH Criteria Document fo r a Rec­
ommended Standard, these recommendations 
concerning MWF are made with the expecta­
tion that they will prevent or greatly reduce the 
risk of adverse health effects in exposed work­
ers. Gathering exposure and health effect data 
related to occupational exposure to engineered 
nanoparticles will be essential when formulat­
ing medical screening programs for workers 
exposed to engineered nanoparticles.
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APPENDIX E • Examples of Limitations in the 
Evidence Base for Specific Medical Screening of 
Workers Exposed to Engineered Nanoparticles
Key among the criteria for recommending spe­
cific medical screening of workers exposed to 
engineered nanoparticles include determining 
whether the substance in question is a hazard 
and whether the disease to be averted is suf­
ficiently common in the worker population to 
justify routine screening [Nasterlack et al. 2007; 
Borak et al. 2006; Halperin et al. 1986]. For 
engineered nanoparticles, there is insufficient 
evidence for a definitive hazard determination. 
Only a small number of the myriad types of 
engineered nanoparticles have undergone ex­
perimental animal inhalation testing, and no 
broad categories of physicochemical risk fac­
tors have been identified to allow for project­
ing hazards across particle types. No chronic 
inhalation studies of engineered nanoparticles 
have been conducted to date. The existence of 
a few short-term inhalation studies on carbon 
nanotubes and nanoscale metal oxides is not 
adequate to identify what disease endpoints to 
assess in medical screening. There is also insuf­
ficient information available regarding the ab­
solute, relative or population-attributable risks 
associated with nanoparticle exposures [Nas­
terlack et al. 2007].
Examples of the issues in determining the ra­
tionale for recommending medical screening 
for workers potentially exposed to engineered 
nanoparticles are described as follows.
Single-Walled Carbon 
Nanotubes (SWCNTs)
Intratracheal (IT) exposure to SWCNTs has 
been associated with interstitial fibrosis in the 
rat (Lam et al. 2004]. Aspiration of purified SW­
CNTs caused rapid and progressive interstitial 
fibrosis in mice [Shvedova et al. 2005]. NIOSH 
has also shown that inhalation of SWCNTs 
cause interstitial fibrosis [Shvedova et al. 2008]. 
The problem is that purified SWCNTs are not 
redox reactive and the interstitial fibrosis is not 
driven by oxidant generation and inflamma­
tion. Therefore, measurement of markers of oxi­
dant stress or inflammation in humans would 
not be predictive. If interstitial lung disease was 
considered the health endpoint of concern, 
monitoring of the carbon monoxide diffusion 
capacity of the lung could be performed nonin- 
vasively. A significant decline in diffusion would 
indicate a loss of alveolar-capillary gas exchange 
and suggest early signs of pre-clinical disease. 
Unfortunately, virtually no published data ex­
ist on occupational exposure concentrations for 
working in SWCNT operations. Consequently, 
there is too little information available at this 
time to verify disease endpoints. There is also 
too little information available on exposure in 
general and ultimately the risk to workers who 
handle these materials.
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Nanoscale Metal Oxides
Pulmonary exposure to nanoscale metal ox­
ides such as titanium dioxide (TiO2) have been 
shown in rat models to cause pulmonary in­flammation [Oberdorster et al. 2005] and to 
inhibit the ability of the systemic microvas­
culature to respond to dilators [Nurkiewicz 
et al.2006; Nurkiewicz et al. in press] after 
IT or inhalation exposures. Ultrafine (nano­
scale) TiO2 has been shown to be more potent 
in causing these effects than fine TiO2 on an 
equivalent mass basis. These effects have been 
associated with oxidant stress and induction of inflammatory mediators. Therefore, markers 
of oxidant stress and inflammation could be 
considered as early indicators of human expo­
sure or response. Oxidant stress markers have 
been suggested as markers of toxicity to metal 
oxide nanoparticles as a class [Nel et al. 2006]. 
Examples of such markers would be nitrous 
oxide or isoprostanes in exhaled breath or 
blood markers of oxidant stress. However, the utility of these markers for screening workers 
exposed to engineered nanoparticles has not been demonstrated. In addition, some research 
shows that nanoscale TiO2 is linked to cancer of the lung and the International Agency for 
Research on Cancer (IARC) has categorized ti­
tanium dioxide as a possible carcinogen to hu­
mans [IARC 2006]. Nonetheless, no evidence 
clearly demonstrates that medical screening 
of asymptomatic workers exposed to lung car­
cinogens decreases the chance of dying from 
cancer (NCI 2007; Marcus et al. 2006).
Nanoscale Cadmium
Cadmium is a substance that has medical screen­
ing recommendations for workers exposed in or­
der to prevent or assess lung and kidney toxicity 
(see Appendices B and C). At a minimum, these 
recommendations should pertain to nanoscale 
cadmium (e.g., such as that used in the produc­
tion of quantum dots). Medical screening is 
typically triggered by the airborne concentra­
tion of the substance in the workplace (e.g., the 
“action level” concentration). An action level is 
some fraction, usually 50%, of an occupational 
exposure limit (OEL). Whether the action level 
concentration recommended for nonnanoscale 
cadmium particles is adequate for nanoscale 
cadmium is unknown. Workplaces with en­
gineered nanoparticles of materials addressed 
by current OSHA standards are subject to the 
requirements of those standards, including the 
requirements for medical surveillance.
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APPENDIX F • Exposure Registries
Exposure registries are useful tools for surveil­
lance of new or perceived hazards. A registry 
provides a structured and orderly approach to handling the problem of identifying and main­
taining communication with workers exposed to 
hazardous substances [Schulte and Kaye 1988]. 
An exposure registry is the enrollment of persons 
exposed or likely to have been exposed to occupa­
tional or environmental hazards; the registry may 
include how these groups are managed with re­
gard to primary or secondary preventive efforts. 
In occupational situations, company employee 
rosters are de facto registries; however, they may 
not address employees who leave a company. 
Moreover, for a new cross-cutting technology 
such as nanotechnology, the registry could enroll 
persons from various companies. Generally, ex­
posure registries are developed and maintained 
by government entities, but there are examples 
of private-sector registries related to exposure to 
commercial products.
The purposes and functions of exposure regis­
tries may be summarized as follows:
• Delineate a population at risk
• Follow cohort to ascertain exposure-dis­
ease associations
• Follow cohort to ensure the institution of 
appropriate primary and secondary pre­
vention and medical surveillance
• Follow cohort to allow for appropriate so­
cial, legal, and economic support
• Demonstrate societal concern for the co­
hort and provide a base for political ac­
tion relevant to the exposure
• Notify a cohort of an exposure, preven­
tive measures, or therapeutic advances 
that were not understood or known at the 
time the registry was established
Various issues should be addressed when con­
sidering development of exposure registries. 
These include the term of the registry, needs of 
registrants, confidentially of information, cost of 
maintaining the registry, and the potential impact 
of the registry on workers and companies.
Registries are essentially a collection of individ­
ual worker information over time with at least 
a preliminary plan for analysis. Data collected 
in registries may be subject to limitations. Ex­
posure registries are not always useful in eti- 
ologic research. For diseases with low preva­
lence following low-level exposures, exposure 
registries are not very effective tools because
(1) exposure classification is often difficult,
(2) the statistical power of prospective studies 
is low, and (3) the time period of the study may be impractically long. Moreover, changes in 
exposures experienced by registry participants 
over time may complicate the ability to estab­
lish clear exposure-disease relationships.
Exposure registries may provide opportunities 
to determine the exposure-disease association 
and risk. Also, when practical prospective stud­
ies can be designed, registries can be used to es­
tablish hypotheses. Many questions arise when considering an exposure registry for etiologic 
research, including:
• How can exposed persons be adequately 
differentiated from nonexposed persons?
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• What group could serve as a comparison 
group so that the disease experience of the 
exposed group can be evaluated?
• How long should the group be followed?
Although exposure registries are useful tools to 
assist populations potentially at risk, their util­
ity for workers exposed to engineered nano­
particles needs further evaluation.
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Delivering on the Nation's promise: 
Safety and health at work for all people 
through research and prevention
To receive NIOSH documents or more information about 
occupational safety and health topics, contact NIOSH at
Telephone: I - 8O O -C D C -IN FO  (1-800-232-4636)
TTY: 1-888-232-6348 
E-mail: cdcinfo@cdc.gov
or visit the NIOSH Web site at w w w .cdc.gov/niosh.
For a monthly update on news at NIOSH, subscribe to 
NIOSH eNews by visiting w w w .cdc.gov/niosh/eNew s.
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